Tirzepatide vs Retatrutide: Body Composition Data From TRIUMPH-4 & SURMOUNT-1

The Lean Mass Problem in GLP-1 and Dual-Agonist Therapy

Weight loss without muscle loss is fiction in most pharmaceutical interventions. When patients achieve 20-30% body weight reduction, lean tissue catabolism inevitably follows—unless the agent preferentially spares skeletal muscle while promoting adipose tissue mobilization.

Two landmark trials published in 2024 reveal a critical difference in body composition outcomes between tirzepatide (Zepbound, a GLP-1/GIP receptor agonist) and retatrutide (a GLP-1/GIP/glucagon receptor agonist): tirzepatide preserves approximately 25% of lost weight as lean mass, while retatrutide loses roughly 37% of weight loss to lean tissue.

This is not academic minutiae. It determines whether a patient emerges from treatment metabolically superior or metabolically compromised.

Dissecting TRIUMPH-4 and SURMOUNT-1 DXA Data

Retatrutide: Maximum Weight Loss, Maximum Lean Tissue Loss

TRIUMPH-4 demonstrated retatrutide's superior total weight reduction: 28.7% body weight loss at the highest maintenance dose (15 mg weekly). This is impressive on the surface. However, the DXA substudy in SURMOUNT-1 (tirzepatide's pivotal trial) revealed a metabolic trade-off.

Retatrutide's triple agonism—simultaneous activation of GLP-1, GIP, and glucagon receptors—drives aggressive fat mobilization and accelerates amino acid oxidation. The glucagon receptor signal, while effective at suppressing appetite and increasing energy expenditure, also upregulates proteolytic pathways in skeletal muscle. Result: lean mass losses constituted 37% of total weight loss.

For a patient losing 30 kg on retatrutide, approximately 11 kg would be muscle tissue. This creates a post-treatment problem: metabolic rate depression and reduced force production.

Tirzepatide: Balanced Weight Loss with Lean Mass Retention

SUMOUNT-1 showed lower total weight loss—21.3% at the 15 mg maintenance dose—but superior body composition. The dual GLP-1/GIP mechanism without glucagon receptor activation preserves lean tissue more effectively.

DXA analysis revealed that lean mass losses constituted only 25% of total weight loss on tirzepatide. For a 25 kg weight loss, approximately 6.25 kg would be muscle—a 40% reduction in lean tissue catabolism compared to retatrutide.

Why? GLP-1 and GIP receptor signaling independently promote satiety and thermogenesis without the systemic protein-catabolizing signal that glucagon activation introduces.

Mechanism: Why Glucagon Receptor Activation Increases Lean Mass Loss

Glucagon, the physiologic counter-regulatory hormone to insulin, mobilizes both hepatic glycogen and amino acids from muscle. At therapeutic doses, retatrutide's glucagon agonism creates a persistent mild catabolic state.

This occurs through:

1. Direct muscle proteolysis: Glucagon receptor signaling on skeletal myocytes upregulates the ubiquitin-proteasome system and autophagy-related genes (FOXO3, TRIM63).
2. Altered amino acid partitioning: Enhanced hepatic gluconeogenesis from branched-chain amino acids (BCAAs), particularly leucine oxidation, reduces anabolic signaling in muscle.
3. Reduced myofibrillar protein synthesis: Glucagon suppresses mTOR signaling in the fed state, even when calories are restricted.

Tirzepatide avoids this penalty. GLP-1 receptor signaling on preproglucagon neurons actually increases endogenous glucagon-like peptide-2 (GLP-2) release, which supports intestinal epithelial integrity and nutrient absorption—partially offsetting lean tissue loss.

Clinical Implications for Protocol Selection

Choose Tirzepatide If:

• You are resistance training and prioritize strength preservation
• Your goal is sustained metabolic rate post-treatment
• You are 18-25% body fat and cannot afford 35+ lbs of muscle loss
• You plan a 12-16 week protocol followed by strength-phase recovery

Baseline labs needed: Total testosterone, free testosterone, IGF-1, metabolic panel, urinalysis. Lean mass preservation correlates with adequate protein intake (1.6-2.2 g/kg) and progressive resistance training.

Consider Retatrutide If:

• Your primary goal is maximum adipose tissue reduction (obesity, severe visceral adiposity)
• You will implement aggressive resistance training during the protocol (mitigates some lean loss)
• You are supplementing with creatine monohydrate (5g daily) and high-quality whey isolate (40g daily minimum)
• Your baseline lean mass index permits 10-15 lbs of loss without functional compromise

Optimizing Lean Tissue Preservation: The Supporting Stack

Regardless of peptide choice, lean mass retention improves with:

Protein: Minimum 0.9-1.2 g per pound of target body weight. Timing around resistance sessions (within 2 hours post-training) amplifies myofibrillar synthesis.

Creatine monohydrate: 5g daily. Enhances phosphocreatine availability, ATP regeneration, and mTOR signaling. Preserves 1-2 lbs of lean mass compared to control over 12 weeks.

Leucine-enriched supplementation: 2-3g free leucine post-training. Activates mTORC1 independent of caloric surplus.

Magnesium glycinate: 300-400mg daily. Supports protein synthesis and cortisol modulation (critical during caloric deficit).

Vitamin D3/K2: 4,000-5,000 IU D3 + 200 mcg K2 (MK-7) daily. D3 upregulates IGF-1 receptor expression in muscle; K2 enhances osteoblast activity and mineral retention.

Resistance training frequency: 4-5x weekly, emphasizing compound movements (squat, deadlift, bench press, row). Progressive overload prevents adaptive thermogenesis.

Testing Before and During Protocol

Day 0 (baseline):

• Complete metabolic panel (CMP)
• Total testosterone, free testosterone, SHBG
• IGF-1 (optional, but useful for GH axis health monitoring)
• Body composition (DEXA scan preferred; bioelectrical impedance acceptable)
• Resting metabolic rate (indirect calorimetry if available)

Week 6-8:

• Repeat body composition if available
• Metabolic panel (ensure kidney function, glucose, electrolytes stable)

End of protocol (week 12-16):

• Full repeat baseline labs
• Body composition
• Strength testing (1RM or estimated 1RM on primary lifts)

Bottom Line

Retatrutide achieves superior total weight loss but at the cost of lean tissue catabolism. Tirzepatide preserves body composition more effectively, making it preferable for individuals whose post-treatment body composition matters as much as total weight loss.

The difference between 25% and 37% lean mass loss may represent 5 lbs of muscle tissue over a 12-week protocol—the difference between emerging stronger and emerging weaker. Protocol selection should reflect whether your goal is adipose tissue destruction (retatrutide) or metabolic optimization (tirzepatide).

Baseline testing and protein-heavy resistance training are non-negotiable regardless of agent choice.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.